N/A N=37 Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2
Critical Illness · Oncology · Communication
Primary: Change in Prognostic Understanding — 0.58; 0.18 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=562 Predictive Analytics and Behavioral Nudges to Improve Palliative Care in Advanced Cancer
Cancer
Primary: Number of Study Participants Who Have Completed a Palliative Care Visit Within 3 Months of Enrollment — 22; 130 participants
Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
N/A N=20 Giving Information Systematically and Transparently in Lung and GI Cancer Phase 1
Critical Illness · Oncology · Communication
Primary: Acceptability of the Proposed Intervention According to a Structured Qualitative Survey of Caregivers — 9; 10; 1; 3 Participants
N/A N=13 Managing Distress in Malignant Brain Cancer
Cancer Metastatic to Brain · Brain Metastases, Adult
Primary: Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains — 3.2; 4.0; 4.0; 3.5 score on a scale
Phase 3 N=405 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Liver Cancer · Anxiety Disorder · Depression
Primary: Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G) — 3.35; 0.12 units on a scale — p=0.104
N/A N=350 Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
Non-small Cell Lung Cancer · Small Cell Lung Cancer · Mesothelioma
Primary: Functional Assessment of Cancer Therapy (Quality of Life Measure) — 81.10; 77.70 units on a scale
Phase 1 N=84 A Study in Advanced Cancer
Advanced Cancer
Primary: Recommended Phase 2 Dose: Maximum Tolerated Dose — 400 milligrams (mg)
N/A N=450 Access to Care and Prognosis in Elderly With Cancer (INCAPAC Study)
Cancer
Primary: Proportion of Patients Being Receiving Treatment Administration After Diagnosis — 372 Participants
Phase 2 N=58 Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
Pancreatic Adenocarcinoma Non-resectable · Pancreatic Adenocarcinoma Metastatic · Colorectal Cancer Metastatic
Primary: Overall Survival - Based on Most Recent Scan — 4.66; 7.7 months
N/A N=507 Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer
Lung Cancer
Primary: Patient-reported Quality of Life — 100.62; 97.75 score on a scale — p=<0.05
N/A N=546 Improving Communication in Older Cancer Patients and Their Caregivers
Adult Solid Neoplasm · Lymphoma
Primary: Direct Communication About Age-related Concerns: Number of Discussions Related to the Geriatric Assessment That Occur in the Clinic Visit Between the Patient, Oncology…
Phase 3 N=472 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
Lung Cancer, Non-Small Cell
Primary: Overall Survival — 4.0; 3.6 months — p=0.1862
N/A N=73 Adolescents and Young Adults (AYAs) With Advanced Cancer
Adolescent and Young Adult Cancer Patient
Primary: Treatment Acceptability Questionnaire — 6.02 score on a scale
Phase 2 N=3 Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1; 2 Participants
N/A N=266 Behavioral Nudges to Improve Palliative Care Utilization in Advanced Cancer
Cancer
Primary: Completion of Palliative Care Visit — 11; 19 Participants
Phase 2 N=45 Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared to Best Supportive Care in Colorectal Cancer Patients
Colorectal Cancers
Primary: Overall Survival — 9.25 months
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
N/A N=57 Self-affirmation Intervention for People Newly Diagnosed With Advanced Cancer
Neoplasms
Primary: Mean Changes From Baseline in Self-esteem Scores on the Rosenberg Self-esteem Scale (RSES) to Two-, Six-, and Eight Weeks Post Baseline — 23.4; 23.5; 23.7; 24.2 score on…
N/A N=213 Engagement of Patients With Advanced Cancer
End of Life · Advanced Cancer · Lung Neoplasm
Primary: Number of Participants With Completed Goals of Care Documentation. We Will Evaluate if 75% of Patients in the Intervention Arm Have a Documented Goals of Care Titled…
Phase 2 N=48 Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
Neoplasms, Unknown Primary
Primary: Progression Free Survival — 3.7 months
Phase 2 N=216 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
Cancer
Primary: Dose Limiting Toxicities (DLT) in the Trial Subjects. — 0; 0; 0; 0 DLT
N/A N=17 Ketogenic Diet in Advanced Cancer
Cancer
Primary: To Determine the Safety and Tolerability of a Modified Low Carbohydrate Diet in People With Advanced Cancer Across Different Tumor Types. — 11 participants
Phase 2 N=69 Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
Breast Cancer
Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort
N/A N=4,322 Care Coordination for Complex Cancer Survivors in an Integrated Safety Net System
Breast Cancer · Colorectal Cancer
Primary: Proportion of Complex Cancer Survivors Meeting Quality of Care Guidelines for Chronic Conditions and Follow-up Cancer Surveillance
N/A N=28 Patient-caregiver Communication Intervention for Prognostic Understanding
Advanced Cancer
Primary: Change in Prognostic Understanding — 0.00; 0.25 Change in scores on a scale
Phase 2 N=37 Cabozantinib in Advanced Solid Malignancies
Lung Cancer · Solid Tumor (Not Breast or Prostate Cancers)
Primary: Number of Participants With Bone Bio-marker Response — 13; 9; 8 Participants
Phase 2 N=30 Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
N/A N=364 Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Lymphoma · Digestive System Diseases · Ovarian Diseases
Primary: Number of Participant Deaths — 56 Participants
N/A N=151 Palliative Care Interventions for Outpatients Newly Diagnosed With Lung Cancer: Phase II
Lung Cancer
Primary: Change From Baseline in Functional Assessment of Cancer Therapy-Lung Total Outcome Index Score at Final Visit — 1.8; -1.2 score on a scale